Cytomegalovirus antibodies in epileptics receiving diphenylhydantoin

Publisher Website
Google Scholar
Abstract
Cytomegalovirus (CMV) antibodies were determined by indirect haemagglutination in 53 epileptics receiving long‐term diphenylhydantoin (DPH) therapy and in 53 matched controls. Absorption of serum IgG, IgA and IgM performed in 12 sera showed that the antibodies were of the IgG class. A decreased incidence of high CMV antibody titres ( 320) was found in epileptics (11.3%) compared with controls (34.0%) (0.02 > P > 0.01), whereas antibody titres 40 were found in 37.7% of epileptics and in 45.3% of controls (n.s.). The CMV antibody incidence and titre range were similar in patients with symptomatic (37.9%) and idiopathic (37.5%) epilepsy, suggesting that the DPH treatment was responsible for the decreased antibody occurrence in patients. No correlation between CMV antibody titres and the serum immunoglobulin levels or the DPH concentration or clearance could be established in the epileptics.